- Home
- DLY vs NUVB Comparison
DLY vs NUVB Comparison
Compare DLY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- NUVB
- Stock Information
- Founded
- DLY 2019
- NUVB 2018
- Country
- DLY United States
- NUVB United States
- Employees
- DLY N/A
- NUVB N/A
- Industry
- DLY Investment Managers
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- DLY Finance
- NUVB Health Care
- Exchange
- DLY Nasdaq
- NUVB Nasdaq
- Market Cap
- DLY 790.9M
- NUVB 679.9M
- IPO Year
- DLY N/A
- NUVB N/A
- Fundamental
- Price
- DLY $14.73
- NUVB $1.61
- Analyst Decision
- DLY
- NUVB Strong Buy
- Analyst Count
- DLY 0
- NUVB 6
- Target Price
- DLY N/A
- NUVB $8.33
- AVG Volume (30 Days)
- DLY 215.9K
- NUVB 2.8M
- Earning Date
- DLY 01-01-0001
- NUVB 05-13-2025
- Dividend Yield
- DLY 8.93%
- NUVB N/A
- EPS Growth
- DLY N/A
- NUVB N/A
- EPS
- DLY N/A
- NUVB N/A
- Revenue
- DLY N/A
- NUVB $7,873,000.00
- Revenue This Year
- DLY N/A
- NUVB $75.73
- Revenue Next Year
- DLY N/A
- NUVB $440.21
- P/E Ratio
- DLY N/A
- NUVB N/A
- Revenue Growth
- DLY N/A
- NUVB N/A
- 52 Week Low
- DLY $13.26
- NUVB $1.64
- 52 Week High
- DLY $15.95
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- DLY 21.62
- NUVB 30.67
- Support Level
- DLY $16.00
- NUVB $1.66
- Resistance Level
- DLY $16.13
- NUVB $1.85
- Average True Range (ATR)
- DLY 0.13
- NUVB 0.11
- MACD
- DLY -0.05
- NUVB -0.02
- Stochastic Oscillator
- DLY 16.51
- NUVB 5.30
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).